KF-1601

Star1

DB18297ExperimentalSmall molecule

KF-1601: Overview.

Mechanism: Pharmacologically active on Tyrosine-protein kinase ABL1 and Receptor-type tyrosine-protein kinase FLT3
Curator reviewed
Formula / weight: C₃₅H₃₀FN₉O · 611.685 g/mol (avg)
Also known as: Benzamide, N-[3-(1-cyano-1-methylethyl)-5-(4-methyl-1H-imidazol-1-yl)phenyl]-2-fluoro-4-methyl-5-[2-[8-[(1-methyl-1H-pyrazol-4-yl)amino]imidazo[1,2-a]pyridin-3-yl]ethynyl]- · N-(3-(2-cyanopropan-2-yl)-5-(4-methyl-1H-imidazol-1-yl)phenyl)-2-fluoro-4-methyl-5-((8-((1-methyl-1H-pyrazol-4-yl)amino)imidazo[1,2-a]pyridin-3-yl)ethynyl)benzamide
Code names: KF-1601

Resolves to

Compound

UNIIA3F7DA3SGXCAS2699634-21-2

Structure

InChIKeyZYJGSUKMQPXJRU-UHFFFAOYSA-NSMILESCN1C=C(NC2=CC=CN3C(=CN=C23)C#CC2=C(C)C=C(F)C(=C2)C(=O)NC2=CC(=CC(=C2)N2C=NC(C)=C2)C(C)(C)C#N)C=N1

Targets

P00519ABL1P36888FLT3

What you can answer from here — as of August 30, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with KF-1601, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account